Research location

Berlin

New Jersey, United States

Published trials209

Site observations210

Linked trials published209

Page2 / 5

Research activity in Berlin

New Jersey, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 209 trials and 210 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Berlin

209 linked trials · page 2 of 5

Mechanistic Evaluation of Response in TRD (MERIT)NCT04608396 · 2020-08-13 · 1 site observation

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult ParticipantsNCT04484337 · 2020-07-31 · 1 site observation

Dexmedetomidine in the Treatment of Agitation Associated With SchizophreniaNCT04268303 · 2020-01-24 · 1 site observation

A Study of Psilocybin for Major Depressive Disorder (MDD)NCT03866174 · 2020-01-23 · 1 site observation

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia PatientsNCT04572685 · 2020-01-22 · 1 site observation

Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs PlaceboNCT04221230 · 2020-01-03 · 1 site observation

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With SchizophreniaNCT04158687 · 2019-11-26 · 1 site observation

A Phase 2b Diabetic Kidney Disease StudyNCT04170543 · 2019-11-18 · 1 site observation

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive DisorderNCT04007367 · 2019-08-06 · 1 site observation

Open-Label Safety Study of AXS-05 in Subjects With DepressionNCT04039022 · 2019-07-08 · 1 site observation

A Trial of AXS-05 in Patients With Major Depressive DisorderNCT04019704 · 2019-06-20 · 1 site observation

Sub-Lingual Dexmedetomidine in Agitation Associated With SchizophreniaNCT04010305 · 2019-05-22 · 1 site observation

Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's SubjectsNCT03817684 · 2019-04-30 · 1 site observation

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®NCT03892889 · 2019-04-29 · 1 site observation

A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaNCT03893825 · 2019-04-17 · 1 site observation

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of SchizophreniaNCT03896945 · 2019-02-15 · 1 site observation

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant DepressionNCT03756129 · 2019-02-08 · 1 site observation

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and InsomniaNCT03771664 · 2019-02-04 · 1 site observation

A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I DisorderNCT03854409 · 2019-01-31 · 1 site observation

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia PatientsNCT03751488 · 2018-12-12 · 1 site observation

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive DisorderNCT03672175 · 2018-11-19 · 1 site observation

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)NCT03745820 · 2018-11-15 · 1 site observation

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants AloneNCT03738215 · 2018-11-09 · 1 site observation

Zelquistinel in the Treatment of Adults With Major Depressive DisorderNCT03726658 · 2018-11-08 · 1 site observation

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With SchizophreniaNCT03697252 · 2018-09-18 · 1 site observation

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)NCT03614156 · 2018-08-02 · 1 site observation

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With SchizophreniaNCT03593213 · 2018-07-30 · 1 site observation

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic MedicationNCT03557931 · 2018-07-13 · 1 site observation

Comparative Bioavailability of RisperidoneNCT03527186 · 2018-07-09 · 1 site observation

Study of Rapastinel as Monotherapy in Patients With MDDNCT03560518 · 2018-06-15 · 1 site observation

Zelquistinel in the Treatment of Major Depressive DisorderNCT03586427 · 2018-06-13 · 1 site observation

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDDNCT03051256 · 2018-05-11 · 1 site observation

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With SchizophreniaNCT03503318 · 2018-04-27 · 1 site observation

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive DisorderNCT03446846 · 2018-03-30 · 1 site observation

Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of SchizophreniaNCT03397134 · 2017-12-15 · 1 site observation

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant AsthmaNCT03358147 · 2017-12-13 · 1 site observation

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 MonthsNCT03351244 · 2017-12-07 · 1 site observation

Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes SubjectsNCT03259789 · 2017-11-28 · 1 site observation

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of SchizophreniaNCT03345979 · 2017-11-15 · 1 site observation

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes SubjectsNCT03115112 · 2017-10-12 · 1 site observation

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)NCT02705755 · 2017-09-09 · 1 site observation

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label ExtensionNCT03870880 · 2017-08-25 · 1 site observation

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive DisorderNCT03093025 · 2017-07-03 · 1 site observation

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral NeuropathyNCT03219320 · 2017-06-27 · 1 site observation

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757 · 2017-06-15 · 1 site observation

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute SchizophreniaNCT03160521 · 2017-06-02 · 1 site observation

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver DiseaseNCT03060538 · 2017-03-05 · 1 site observation

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive DisorderNCT03002077 · 2017-02-03 · 1 site observation

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 DiabetesNCT03005288 · 2017-02-01 · 1 site observation

Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586 · 2017-01-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.